Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose SRT2379 endotoxin challenge study in healthy men
NL-OMON36662Phase 1Not yet recruiting
- Sponsor
- Sirtris Pharmaceuticals
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of SRT2379 in chronic inflammation (2 arms), sponsored by Sirtris Pharmaceuticals. Primary endpoint: Inflammatory response after endotoxin challenge. Planned start Jan 2011; status: not yet recruiting.
02
Drugs
SRT2379
03
Conditions
chronic inflammation
Beyond the preview
Go deeper on NL-OMON36662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36662.